BioVisioN receives research grant within BioChancePLUS program
08-Aug-2005
By investigating the action of several protease inhibitors in animal models, BioVisioN will discover biomarkers for drug efficacy and possible side effects that can be used in early and advanced stages of drug development thus allowing early selection of the optimal drug candidate and the proper selection of patients responding to the drug, speeding up drug development and contributing to cost reduction.
Topics
Organizations
Digilab BioVisioN
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.